摘要 : In an experimental model of Parkinson's disease, the dopamine content in the striatum, the density of TH+ neurons in the substantia nigra, and the motor activity of mice were studied after the administration of afobazole, which in... 展开 In an experimental model of Parkinson's disease, the dopamine content in the striatum, the density of TH+ neurons in the substantia nigra, and the motor activity of mice were studied after the administration of afobazole, which interacts with Sigma-1 and MT(1)receptors and regulatory sites of MAO-A and quinone reductase 2 (NQO2, MT(3)receptor), and its main metabolite M-11, which selectively interacts only with the regulatory site of NQO2. The drugs were administered intraperitoneally for 14 days with the start of the course 30 minutes after unilateral intrastriatal administration of 5 mu g of 6-hydroxydopamine (6-OHDA). Afobazole and M-11 showed neuroprotective properties. In all experiments, the effective dose of afobazole (2.5 mg/kg) was significantly lower than M-11 (7.5 mg/kg). The experimental model used shows the contribution of NQO2 and other drug targets to the antiparkinsonian effect of afobazole. 收起